Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

health direction pty ltd - magnesium amino acid chelate,magnesium ascorbate,magnesium glycinate dihydrate,magnesium phosphate pentahydrate,taurine,zinc amino acid chelate -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

health direction pty ltd - magnesium amino acid chelate, quantity: 350 mg/g (equivalent: magnesium, qty 70 mg/g); zinc amino acid chelate, quantity: 5 mg/g (equivalent: zinc, qty 1 mg/g); magnesium phosphate pentahydrate, quantity: 24 mg/g (equivalent: magnesium, qty 4.96 mg/g); taurine, quantity: 200 mg/g; magnesium ascorbate, quantity: 42 mg/g (equivalent: magnesium, qty 2.6 mg/g); magnesium glycinate dihydrate, quantity: 20.85 mg/g (equivalent: magnesium, qty 2.44 mg/g) - powder, oral - excipient ingredients: stevia rebaudiana; acacia; malic acid; flavour - decrease/reduce/relieve muscle cramps ; helps decrease/reduce/relieve mild muscle spasms/twitches ; maintain/support muscle relaxation ; decrease/reduce/relieve symptoms of stress ; decrease/reduce/relieve headache symptoms ; decrease/reduce/relieve sleeplessness ; decrease/reduce/relieve disturbed/restless sleep ; decrease/reduce/relieve symptoms of premenstrual tension

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amiodarone hydrochloride, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 80; water for injections; benzyl alcohol; hydrochloric acid; sodium hydroxide - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachyardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.,amiodarone hhh injection may be used for treatment initiated in a hospital for severe cases of tachyarrhythmias (atrial, junctional and ventricular) not responding to other therapy and when a rapid response is required. amiodarone hhh injection should only be used where facilities exist for cardiac monitoring and defibrillation should the need arise.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - amiodarone hydrochloride, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 80; benzyl alcohol; water for injections; hydrochloric acid; sodium hydroxide - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachyardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation.,amiodarone gh injection may be used for treatment initiated in a hospital for severe cases of tachyarrhythmias (atrial, junctional and ventricular) not responding to other therapy and when a rapid response is required. amiodarone gh injection should only be used where facilities exist for cardiac monitoring and defibrillation should the need arise.

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2mmol/ml) solution for injection 10ml ampoules (martindale pharmaceuticals ltd - magnesium sulfate heptahydrate - solution for injection - 500mg/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 0.4mmol/ml) solution for injection 10ml ampoules (martindale pharmaceuticals ltd - magnesium sulfate heptahydrate - solution for infusion - 100mg/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2mmol/ml) solution for injection 20ml vials (torbay pharmaceuticals - magnesium sulfate heptahydrate - solution for injection - 500mg/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2mmol/ml) solution for infusion 50ml vials (torbay pharmaceuticals - magnesium sulfate heptahydrate - solution for infusion - 500mg/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2mmol/ml) solution for injection 2ml ampoules (torbay pharmaceuticals - magnesium sulfate heptahydrate - solution for injection - 500mg/1ml

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

magnesium 2mmol/ml) solution for injection 5ml ampoules (torbay pharmaceuticals - magnesium sulfate heptahydrate - solution for injection - 500mg/1ml